Life sciences patent litigation team joins Mintz

The group is led by Sige Gutman, who has over 20 years of industry experience

Life sciences patent litigation team joins Mintz

Mintz has recently welcomed a life sciences patent litigation team to boost its intellectual property capabilities.

The group, led by Siegmund “Sige” Gutman, is expected to enhance Mintz’s position in the legal industry, especially in life sciences litigation. Sige Gutman will take on roles as member, chair of life sciences litigation, and co-chair of patent litigation at Mintz. He is joined by member David Hanna and a team of nearly a dozen attorneys based in Los Angeles, Boston, and New York. This strategic expansion aims to strengthen Mintz’s existing practices in life sciences transactional and patent prosecution, as well as high-tech IP litigation.

“This is a very exciting time for Mintz, and adding Sige to our team elevates us to yet another level,” said Bob Bodian, managing member. “Sige adds to our highly regarded IP practice a best-in-class, immensely respected life sciences litigation practice. That practice complements perfectly our life sciences transactional and patent prosecution practices, as well as our high-tech IP litigation practice. We are delighted to welcome Sige and his team.”  

Gutman has represented life sciences clients in trial and appellate courts and before arbitration panels. With over 20 years of industry experience and a solid educational background in molecular and cell biology and biophysical chemistry, he has served as senior patent litigation counsel for Amgen. Gutman’s expertise includes developing market exclusivity and freedom to operate (FTO) strategies, encompassing patent office and FDA regulatory strategies.

Michael T. Renaud, chair of the Intellectual Property Division at Mintz, highlighted the new team's strategic importance. “Sige is regarded as one of the top life sciences patent litigators in the country. His group is one of the most complete life sciences litigation teams practising in the U.S. today. Their scientific credentials and winning litigation record have earned the trust of the world’s leading life sciences companies.”

David Hanna, joining as a member, brings extensive experience in biologic drug patent and Hatch-Waxman patent litigation, having represented both patentees and generic filers.

Gutman himself expressed optimism about the future at Mintz, “Life Sciences and IP are top priorities at Mintz, which makes it an ideal place for our team to thrive long term. We are excited to join Mintz’s world-class IP practice and look forward to bringing further value to clients through the firm’s multi-disciplinary life sciences platform.”

Recent articles & video

Thomson Geer partner on the biggest impact of the Bruce Lehrmann defamation ruling

Federal Court rules in ASIC's favour against Cigno Australia, BSF Solutions

Senior appointments strengthen CBP offerings

Legal orgs team up to aid community legal centres

HSF environment, planning and communities group partners with CEIG on report

New metric developed to assess socioeconomic challenges of US law school applicants

Most Read Articles

NSW Supreme Court sets trial date for landmark strip search class action

K&L Gates Advises Centuria on acquisition of massive glasshouse in Victoria

Hall & Wilcox assists Tobii Dynavox to acquire Link Assistive for $13m

Pearce IP's AU litigation head shares the most important lesson she learned from her old job